Peptides
Adamax
Also called Adamax
Adamax is marketed to people seeking a stronger or longer-lasting Semax-like boost in focus, motivation and mental energy. Those are the hoped-for benefits, not established improvements. Its modified-peptide label does not prove that it reaches the brain better, lasts longer in people or is interchangeable with Semax.
Dosage & duration
One commercial guide’s reported range
True North overview row
Reported use · unapproved regimen- Dose
- 300–1,000 mcg per day
- How often
- Once daily, subcutaneous
- How long
- 8–12 weeks in that guide
Describes the guide’s range across its proposed schedule, not an established starting or maintenance dose. No efficacy or safe-cycle validation supplied.
Sources: 2
The source’s escalation and equal-length-break claims are not adopted. No Semax-to-Adamax dose conversion is established.
The practical difference
Is Adamax a Semax upgrade?
Focus and staying power are the appeal, but the upgrade claims remain unproven.
| Question | The pitch | What is established |
|---|---|---|
| Better focus | A stronger Semax-like effect | No verified direct clinical comparison establishes superiority. |
| Longer lasting | More staying power | Longer duration in people is not established. |
Why do people compare Adamax with Semax?
The attraction is a perceived upgrade: more focus, motivation or staying power from less material. Marketing descriptions often borrow the Semax literature, but a derivative needs its own testing. Related chemistry cannot tell us how a person will feel.
What can the online amount tell you?
It tells you what one guide proposes, not what most users take or what clinical studies established. The source supplies a detailed schedule without Adamax-specific outcome evidence. We show its range as attributed context, not a reason to escalate toward the top.
Product identity comes first
A name on a vial and a generic purity percentage do not establish that every supplier sells the same structure. This also limits comparisons between reports. Record the exact product rather than assuming all “Adamax” experiences are interchangeable.
What would a useful benefit look like?
Judge the intended task, sleep and unwanted effects separately. More mental activation with worse sleep may not be a net improvement. The plot cannot predict cognition or establish that a longer assumed half-life is better.
Model details: Adamax · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Legacy 0.48 h is not source-backed; evidence reviewed does not establish that acetylation/amidation or another modification confers a numeric extension.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 0.48 hours
- Absorption half-life assumed
- 0.12 hours
- Reference amount for the relative scale
- 1 mg
- Absorption half-life is assumed to be one quarter of the slower timescale (0.12 h); it is not a measured absorption parameter.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Compound identity can differ among vendor descriptions.
- No compound-specific administered-human calibration established in reviewed records.
- Medsafe — June 2025 peptide classification submission
Legacy 0.48 h is not source-backed; evidence reviewed does not establish that acetylation/amidation or another modification confers a numeric extension.
adamax-relative-timing-2026-10 · version 1
Common questions
Is Adamax definitely longer-lasting than Semax?
The reviewed evidence does not establish a measured human comparison. A structural explanation is not a human duration study.
Can I divide my Semax dose by a potency factor?
No verified conversion factor exists. Different identity, route and formulation make that arithmetic misleading.
Sources Labels, studies and notes behind this guide
Catalog evidence: Product or community reports. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- Main appeal
- A stronger sensation is not proof of better cognitive performance.
- Versus Semax
- Semax studies do not test Adamax’s modified product.
- Duration claims
- Chemical modification alone does not establish a human half-life.
- 1. Medsafe peptide classification submission, 2025
Official submission inspected: marketed ACTH analogues including Adamax; not clinical efficacy or structure validation.
- 2. True North Health Labs Adamax guide
Commercial guide fully inspected. Overview lists 300–1000 mcg daily SC for 8–12 weeks; asserted enhanced brain entry and tolerance-prevention claims are unsupported and not adopted.
- 3. Medsafe — June 2025 peptide classification submission
Legacy 0.48 h is not source-backed; evidence reviewed does not establish that acetylation/amidation or another modification confers a numeric extension.
- 4. Eremin et al. 2005 — parent Semax experiment
Defines and tests Semax in rodents, not Adamax; included only to make the parent/derivative boundary clear.
- 5. PubMed — Adamax peptide search
Name/peptide search checked October 7, 2026; no compound-specific clinical or PK study located. Search absence is not proof no unindexed research exists.
Related compounds and examples
Related compounds
Semax
Semax for focus and mental fatigue: nasal-drop examples, concentration differences and realistic expectations for everyday nootropic use.
Selank
Selank for anxiety and calm focus: nasal-drop context, comparison with Semax and what to expect from the limited human research.
Cerebrolysin
Cerebrolysin for cognition and recovery questions: clinical dose context, why milliliters matter and how nootropic goals differ from stroke research.